Engle Martin Announces the Acquisition of Integra, Advancing Specialty Claims Expertise Globally
7.10.2025 14:00:00 EEST | Business Wire | Press release
Engle Martin & Associates, LLC (“Engle Martin”), a market-leading independent loss adjusting and claims management provider, announced today its acquisition of Integra Technical Services Group (“Integra”), a specialty international loss adjusting firm headquartered in London, England.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251007106413/en/
Founded in 1998, Integra has built a strong reputation for managing high-value and complex claims across a range of specialty industries, including construction and engineering, energy, manufacturing, advanced technologies, mining, marine, specialist liabilities, and risk engineering. With over 50 experienced claims professionals and offices strategically located throughout the United States, Europe, Asia, Australia, New Zealand, the Middle East, and Latin America, Integra delivers expert-led adjusting solutions that align with the unique challenges of global markets.
“This is an exciting and meaningful milestone for Engle Martin,” said Stephen Beene, President of Engle Martin. “The addition of Integra not only accelerates our global strategy but also brings a talented team with deep technical knowledge and a respected market presence. We share a culture that values people and performance as well as a commitment to delivering innovative, high-quality service to clients. We’re proud to welcome Integra to the Engle Martin family.”
Integra will continue operating as a standalone business, retaining its established brand, leadership team, and service model. The current leadership will maintain full operational oversight of the company’s portfolio, ensuring continuity for clients and team members.
“This acquisition marks a strategic step in Engle Martin’s continued growth and international expansion,” commented Jay Campbell, Executive Vice President – Strategy & Organizational Growth at Engle Martin. “It enhances our capabilities in large loss adjusting and specialty sectors, strengthens our operations in the United States, and significantly broadens our global reach. By combining our complementary strengths, we are better positioned to meet the evolving needs of clients worldwide.”
Ewan Cresswell, Chairman and Founder of Integra, added, “Joining Engle Martin marks a new and significant chapter for Integra. This partnership aligns with our values, provides greater operational support, and strengthens our presence in the United States, while enabling us to continue serving clients across both established and emerging markets. This alignment enhances our global platform while preserving the specialized services and high technical expertise that define Integra.”
This acquisition strengthens Engle Martin’s position as a trusted global partner in loss adjusting and claims management, while underscoring its continued investment in talent, innovation, and international service expansion.
About Engle Martin:
Engle Martin & Associates, LLC is a market-leading independent loss adjusting and claims management provider. Engle Martin offers a comprehensive suite of services, including commercial property, casualty, inland and ocean marine, appraisal/umpire, and specialty audits. With over 800 claims professionals across 75 U.S. locations, Engle Martin is committed to delivering results-driven and client-focused solutions. Learn more at www.englemartin.com
About Integra:
Integra Technical Services Group is a specialty international adjusting business established in 1998, with a reputation for having the abilities and experience to manage technical and specialist claims, as well as risk engineering globally. Integra is committed to being the loss adjuster of choice in every industry sector it serves by delivering technically based, high-quality service, and excellence in every appointment. Learn more at www.integratechnical.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20251007106413/en/
Contacts
Media Contacts:
Engle Martin
Dominique Enriquez
Marketing Director
denriquez@englemartin.com
Integra
Doug Horne
Global Head of Marketing
doug.horne@integratechnical.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom